Growing Prevalence of Cancer and Genetic Disorders
The growing prevalence of cancer and genetic disorders patients have a direct rising impact on the increased demand of the molecular cytogenetic market. The related growth in mortality per year due to cancer in particular, has significantly driven this market. The techniques such as fluorescence in situ hybridization (FISH) has given significant insights regarding cancer genomics with the rapid and precise characterization of chromosomal anomalies for an early diagnosis, prognosis optimization, and opportunity for cure. The monogenic diseases are highly responsible for the heavy loss of life with a global prevalence of nearly 10/1000 as per the World Health Organization (WHO). Thus, the prevalence of life-threatening diseases plays a vital role in driving this market.
Other driving factors include increasing focus toward the targeted therapy for cancer treatment, the rise in funding for research and clinical diagnosis and technological advancements in cytogenetic techniques.
High Cost of Overall Diagnostic Treatment
The high cost of overall diagnostic treatment related to cytogenetics and hospitalization of patients is one of the primary factor restricting the growth of this market. One of the cases is related to Down syndrome screening programmes where 80% of antenatal karyotypes are generated, and rapid aneuploidy diagnosis (RAD) is one of the standalone approaches but is expensive. Furthermore, delay in diagnosis and treatment often leads to increased hospitalization stay and overall cost. As per a 2015 published article in the Jornal de Peditria, the high cost limited the widespread use of the chromosomal karyotype such as chromosomal microarrays.
Other factors limiting the growth of this market are the ambiguous scenario of regulatory guidelines and reimbursement, as well as, the lack of awareness about the emerging diagnostic technologies for cytogenetics.
Asia-Pacific to Register the Fastest Growth Rate
Asia-Pacific is expected to register the fastest growth rate in the forecast period. The healthy CAGR is expected due to the surge in the scientific researches in countries, such as India, China, Japan, and Malaysia due to funding from government and companies collaborating with research centers. The novel opportunities are further enhanced by the rising number of long-term collaborations of multinational companies with domestic manufacturers and research laboratories in this region. This is followed by the diversified patient pool suffering from cancer and genetic disorders.
The North America region is expected to dominate the market with a large number of clinical research laboratories and academic institutes with better regulatory framework in the countries of this region.
Key Developments in the Market
- January 2018 - Precipio Inc collaborated with the cytogenetics laboratory at the University of Pennsylvania, for conducting an external validation and evaluation of IV-Cell, Precipio’s cytogenetics media.
Reasons to Purchase the Report
- Current and future of the global molecular cytogenetics market outlook in the developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- The segment that is expected to dominate the market.
- Regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1.1 Growing Prevalence of Cancer and Genetic Disorders
6.1.2 Rising Focus Toward the Targeted Therapy for Cancer Treatment
6.1.3 Rise in Funding for Research and Clinical Diagnosis
6.1.4 Technological Advancements in Cytogenetics Techniques
6.2.1 High Cost of Overall Diagnostic Treatment
6.2.2 Ambiguous Scenario of Regulatory Guidelines and Reimbursement
6.2.3 Lack of Awareness About the Emerging Diagnostic Technologies for Cytogenetics
6.4 Key Challenges
7. Market Segmentation
7.1 By Technique
7.1.1 Fluorescence in Situ Hybridization
7.1.2 In Situ Hybridization
7.1.3 Comparative Genomic Hybridization
188.8.131.52 Array-based Comparative Genomic Hybridization
184.108.40.206 Standard Comparative Genomic Hybridization
7.1.6 Other Techniques
7.2 By Application
7.2.1 Genetic Disorders
7.2.3 Personalized Medicine
7.2.4 Other Applications
7.3 By Product
7.3.3 Software and Services
7.4 By End User
7.4.1 Biopharmaceutical Companies
7.4.2 Research Laboratories
7.5 By Geography
7.5.1 North America
220.127.116.11 United States
18.104.22.168 Rest of North America
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
7.5.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
7.5.5 South America
22.214.171.124 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Agilent Technologies, Inc.
9.3 Applied Spectral Imaging, Inc.
9.4 Bio-Rad Laboratories, Inc.
9.5 Cytognomix, Inc.
9.6 F. Hoffmann-La Roche Ltd
9.7 Illumina, Inc.
9.8 PerkinElmer, Inc.
9.9 Quest Diagnostics Incorporated
9.10 Thermo Fisher Scientific
*List not Exhaustive
10. Future of the Market
- Agilent Technologies Inc.
- Applied Spectral Imaging Inc.
- Bio-Rad Laboratories Inc.
- Cytognomix Inc.
- F. Hoffmann-La Roche Ltd
- Illumina Inc.
- Perkinelmer Inc.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific